BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Chinese Patent Office
Federal Trade Commission
Queensland Health
Cantor Fitzgerald

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,163,798

« Back to Dashboard

Which drugs does patent 8,163,798 protect, and when does it expire?

Patent 8,163,798 protects CONCERTA and is included in one NDA. There have been two Paragraph IV challenges on Concerta.

Protection for CONCERTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,163,798

Title:Methods and devices for providing prolonged drug therapy
Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s): Gupta; Suneel K. (Sunnyvale, CA), Guinta; Diane R. (Palo Alto, CA), Christopher; Carol A. (Belmont, CA), Saks; Samuel R. (Burlingame, CA), Hamel; Lawrence G. (Mountain View, CA)
Assignee: Alza Corporation (Palo Alto, CA)
Application Number:10/639,355
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-001Aug 1, 2000ABRXYesNo► Subscribe► SubscribeY► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-004Apr 1, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-002Aug 1, 2000ABRXYesNo► Subscribe► SubscribeY► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-003Dec 8, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Farmers Insurance
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: